Search

Displaying results 1051 - 1060 of 3917 in total
  1. Drug

    Bivalirudin

    go.drugbank.com/drugs/DB00006
    ApprovedInvestigational

    Bivalirudin is a synthetic 20 residue peptide (thrombin inhibitor) which reversibly inhibits thrombin. Once bound to the active site, thrombin cannot activate fibrinogen into fibrin, the crucial step in the formation of thrombus. It is a...

  2. Drug

    Lansoprazole

    go.drugbank.com/drugs/DB00448
    ApprovedInvestigational

    Lansoprazole marketed under the brand Prevacid, is a proton pump inhibitor (PPI) and is structurally classified as a substituted benzimidazole. It reduces gastric acid secretion by targeting gastric H,K-ATPase pumps and is thus effective...

    Products: MICROGRANULOS CON CUBIERTA ENTÉRICA
  3. Drug

    Avatrombopag

    go.drugbank.com/drugs/DB11995
    ApprovedInvestigational

    Avatrombopag (Doptelet), is an orally administered, small molecule thrombopoietin receptor (c-Mpl) agonist that increases platelet number without increasing platelet activation, thereby decreasing the need for blood transfusions. Patient...

  4. Drug

    Mineral oil

    go.drugbank.com/drugs/DB11057
    ApprovedInvestigationalVet approved

    Mineral oil, or paraffin oil, is a mixture of higher alkanes from a mineral source, such as petroleum. Petroleum mineral oil is manufactured from crude oils by vacuum distillation to produce several distillates and a residual oil that ar...

    Mixtures: AGAROL CON SABOR A FRAMBUESAProducts: PARAFFINA LIQUIDA MARCO VITI
  5. Drug

    Elotuzumab

    go.drugbank.com/drugs/DB06317
    ApprovedInvestigational

    Elotuzumab was approved on November 30, 2015 by the U.S. Food and Drug Administration. Elotuzumab is marketed under the brand Empliciti™ by Bristol-Myers Squibb.

  6. Drug

    Navepegritide

    go.drugbank.com/drugs/DB17824
    ApprovedInvestigational

    allows for once-weekly dosing while providing sustained systemic exposure to CNP, which antagonizes the overactive fibroblast growth factor receptor 3 (FGFR3) signaling pathway responsible for impaired bone

  7. Drug

    Phentolamine

    go.drugbank.com/drugs/DB00692
    ApprovedInvestigational

    Phentolamine is a reversible, non-selective alpha-adrenergic blocker that induces vasodilation.

    Categories: Non-selective Alfa-adrenergic Blocking Agents
  8. Drug

    Chlorothiazide

    go.drugbank.com/drugs/DB00880
    ApprovedInvestigationalVet approved

    A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p812)

  9. Drug

    Quinethazone

    go.drugbank.com/drugs/DB01325
    Approved

    Quinethazone, marketed as Hydromox, is a thiazide diuretic indicated for hypertension. Patients may experience adverse reactions such as dizziness, dry mouth, nausea, and hypokalemia.

  10. Drug

    Pegvaliase

    go.drugbank.com/drugs/DB12839
    ApprovedInvestigational

    Pegvaliase is a recombinant phenylalanine ammonia lyase (PAL) enzyme derived from Anabaena variabilis that converts phenylalanine to ammonia and trans-cinnamic acid . Both the U.S. Food and Drug Administration and European Medicines Agen...